Bristol-myers Squibb Compnay

Medarex Inc.

Oxford Biotherapeutics Ltd

E. R. Squibb Sons, Inc.

Chetana Rao-Naik

Jonathan Alexander Terrett

Kristopher Toy

Sarah Lee Pogue

Bingliang Chen

Lan Yang

Haichun Huang

David J King

David B Passmore

Heidi N Leblanc

Chin Pan

Dawn M Tanamachi

Alison Witte

Mark Yamanaka

Richard Theolis

Kyra D Zens

Tim Sproul

Asna Masood

Erika Meaddough

Sarah R Reed

Paul O Sheppard

Mohan Srinivasan

Arvind Rajpal

Josephine M Cardarelli

Jie Liu

Stanley Richard Krystek, Jr

Gregory D Vite

Yong Zhang

Pavel Strop

Paul E Morin

Shrikant Deshpande

Michelle Renee Kuhne

Virginie Lafont

Xiaodi Deng

Alla Pritsker

Zheng Lin

Alasdair Fraser Bell

Sharline Chen

To Uyen Thi Do

Sayumi Yamazoe

Patrick G Holder

David John King

Sara R Dwiggins

An antibody has a glutamine-containing extension at the C-terminus of a light chain thereof, making it suitable for conjugation via transglutaminase-mediated transamidation.

Antibody comprising a glutamine-containing light chain C-terminal extension, conjugates thereof, and methods and uses

A prodrugged antibody has a blocking moiety attached to a Cys on its heavy or light chain via a linker having a cleavable moiety. The blocking moiety inhibits binding of the antibody to its antigen. Cleavage of the cleavable moiety releases the blocking moiety and restores ability of the antibody to bind to its antigen.

Prodruggable antibodies, prodrugs thereof, and methods of use and making

An antibody has at a heavy chain thereof a C-terminal extension that includes at least one glutamine that is a substrate for transglutaminase, enabling the transglutaminase-mediated preparation antibody-drug conjugates using such antibody.

Antibodies conjugatable by transglutaminase and conjugates made therefrom

The invention provides antibodies which bind to the extracellular domain of the Tyrosine-protein kinase transmembrane receptor Matriptase. Nucleic acid molecules encoding the antibodies, expression vectors, host cells and methods for expressing the antibodies are also provided. The antibodies may be used for the treatment of cancer, including gastric cancer, colorectal cancer, prostate cancer, breast cancer, ovarian cancer lung cancer, preferably SCLC, esophageal cancer, head and neck cancer, pancreatic cancer, lymphoma preferably non-Hodgkin's lymphoma and skin cancer.

Antibodies

The present disclosure provides isolated monoclonal antibodies that specifically bind to CD22 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CD22, as well as methods for treating various cancers and inflammatory and autoimmune disorders using an anti-CD22 antibody of this disclosure.

Human antibodies that bind CD22 and uses thereof

The present disclosure provides isolated monoclonal antibodies that specifically bind to mesothelin with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human mesothelin. In certain embodiments, the antibodies are capable of internalizing into mesothelin-expressing cells or are capable of mediating antigen dependent cellular cytotoxicity. The invention further provides anti-mesothelin antibodies that can inhibit the binding of mesothelin to the ovarian cancer antigen CA125. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting mesothelin, as well as methods for treating cancers, such as mesotheliomas, pancreatic cancers and ovarian cancers, using an anti-mesothelin antibody of this disclosure.

Human antibodies that bind mesothelin, and uses thereof

The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, more particularly engineered antibodies resulting in increased binding to Fc receptors and/or increased potency for ADCC or immunoconjugates, which specifically bind to CADM1 with high affinity. Nucleic acid molecules encoding CADM1 antibodies, expression vectors, host cells and methods for expressing the CADM1 antibodies are also provided. Bispecific molecules and pharmaceutical compositions comprising the CADM1 antibodies are also provided. Methods for detecting CADM1, as well as methods for treating various cancers, including lung cancer and pancreatic cancer, are disclosed.

Fully human antibodies specific to CADM1

The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to CD19 with high affinity. Nucleic acid molecules encoding such CD19 antibodies, expression vectors, host cells and methods for expressing the CD19 antibodies are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the CD19 antibodies are also provided. Methods for detecting CD19, as well as methods for treating various B cell malignancies, including non-Hodgkin's lymphoma, are disclosed.

CD19 antibodies and their uses

Growing community of inventors

Walnut Creek, CA, United States of America

Chetana Rao-Naik